ReviewGastroenterology clinics of North America2021
Post-infection Irritable Bowel Syndrome.
Review in Gastroenterology clinics of North America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- A randomized open label pilot study evaluating the efficacy of two dosing regimens of rifamycin SV MMX in the treatment of small intestinal bacterial overgrowth.BMC gastroenterology · 2025Trial
- Gut microbiome dynamics in acute infectious diarrhea: A conceptual framework from acute dysbiosis toward precision restoration (Review).Experimental and therapeutic medicine · 2026Review
- The Cost of the Cure: Antibiotic Exposure as a Risk Factor for Irritable Bowel Syndrome.Antibiotics (Basel, Switzerland) · 2026Review
- Postinfectious Syndromes and Long-Term Sequelae after Giardia Infections.Emerging infectious diseases · 2025Review
- Comparison of sociodemographic factors, lifestyle, and gastrointestinal symptoms between patients with endometriosis and IBS.BMC gastroenterology · 2025Article
- Post-infectious irritable bowel syndrome in a paediatric population: first data in a Middle Eastern country.BMC pediatrics · 2025Article
- Article
- Pediatric Gastrointestinal Tract Outcomes During the Postacute Phase of COVID-19.JAMA network open · 2025Article
- Atractylenolide I ameliorates post-infectious irritable bowel syndrome by inhibiting the polymerase I and transcript release factor and c-Jun N-terminal kinase/inducible nitric oxide synthase pathway.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Long-term symptoms in children after a Cryptosporidium hominis outbreak in Sweden: a 10-year follow-up.Parasitology research · 2025Article
- Interaction between gut microbiota and immunity in health and intestinal disease.Frontiers in immunology · 2025Review
- Inflammasomes in Intestinal Disease: Mechanisms of Activation and Therapeutic Strategies.International journal of molecular sciences · 2024Review
- Microbiome Shifts and Their Impact on Gut Physiology in Irritable Bowel Syndrome.International journal of molecular sciences · 2024Review
- Impact of Enteric Nervous Cells on Irritable Bowel Syndrome: Potential Treatment Options.Microorganisms · 2024Review
- Insights Into the Role of the Microbiome in Irritable Bowel Syndrome.Gastroenterology & hepatology · 2024Article
- Leaky Gut Syndrome: Myths and Management.Gastroenterology & hepatology · 2024Article
- Pediatric Gastrointestinal Outcomes During the Post-Acute Phase of COVID-19: Findings from RECOVER Initiative from 29 Hospitals in the US.medRxiv : the preprint server for health sciences · 2024Article
- Can diet change the natural history of gastrointestinal diseases?JGH open : an open access journal of gastroenterology and hepatology · 2024Review
- Putting Functional Gastrointestinal Disorders within the Spectrum of Inflammatory Disorders Can Improve Classification and Diagnostics of These Disorders.Biomedicines · 2024Review
- The influence of Nav1.9 channels on intestinal hyperpathia and dysmotility.Channels (Austin, Tex.) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Epidemiologic data support that acute gastrointestinal infection is one of the strongest risk factors for development of irritable bowel syndrome (IBS). Risk of post-infection IBS (PI-IBS) seems to be greater with bacterial and protozoal than viral enterocolitis. Younger individuals, women, and those with severe enterocolitis are more likely to develop PI-IBS. Disease mechanisms in animal models and humans involve chronic perturbation of intestinal microbiome, epithelial and neuronal remodeling, and immune activation. These mechanisms can lead to luminal (increased proteolytic activity, altered bile acid composition) and physiologic (increased permeability, transit changes, and visceral hypersensitivity) alterations that can mediate PI-IBS symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.